Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review

Ahmed Abbas, Yusuf A. Rajabally

Research output: Contribution to journalReview article

Abstract

BACKGROUND: Intravenous Immunoglobulin (IVIg) forms a cornerstone of effective treatment for acute and chronic inflammatory neuropathies, with a class I evidence base in Guillain-Barré Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). It is generally considered to be a safe therapy however there are several recognised complications which are reviewed in this article. DISCUSSION AND CONCLUSION: Most adverse events are immediate and mild such as headache, fever and nausea although more serious immediate reactions such as anaphylaxis may rarely occur. Delayed complications are rare but may be serious, including thromboembolic events and acute kidney injury, and these and associated risk factors are also discussed. We emphasise the importance of safe IVIg administration and highlight practical measures to minimise complications of this therapy.

Original languageEnglish
Pages (from-to)3-13
Number of pages11
JournalCurrent drug safety
Volume14
Issue number1
DOIs
Publication statusPublished - 31 Jan 2019

    Fingerprint

Keywords

  • Adverse event
  • CIDP
  • GBS
  • immunoglobulin
  • inflammatory neuropathy
  • IVIg
  • MMN
  • safety.

Cite this